bluuebunny/crossref_metadata_2025_split huggingface dataset:
Development of monoclonal antibodies targeting the conserved fragment of hexon protein to detect different serotypes of human adenovirus
Authors: Wu Linfan , Lin Yuhao , Yin Juzhen , Yang Changbi , Jiang Yushan , Zhai Linlin , Wang Yuelin , Zhu Li , Wu Qinghua , Zhang Bao , Wan Chengsong , Zhao Wei , Yang Yang , Shen Chenguang , Xiao Weiwei 
Published: February 2024

ABSTRACT

Human adenovirus (HAdV) infects the respiratory system, thus posing a threat to health. However, immunodiagnostic reagents for human adenovirus are limited. This study aimed to develop efficient diagnostic reagents based on monoclonal antibodies for diagnosing various human adenovirus infections. Evolutionary and homology analyses of various human adenoviral antigen genes revealed highly conserved antigenic fragments. The prokaryotic expression system was applied to recombinant penton, hexon, and IVa2 conserved fragments of adenovirus, which were injected into BALB/c mice to prepare human adenovirus-specific monoclonal antibodies. Enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence assay (IFA), and Western blotting were used to determine the immune specificity of the monoclonal antibodies. Indirect ELISA showed that monoclonal antibodies 1F10, 8D3, 4A1, and 9B2 were specifically bound to HAdV-3 and HAdV-55 and revealed high sensitivity and low detection limits for various human adenoviruses. Western blotting showed that 1F10 and 8D3 specifically recognized various human adenovirus types, including HAdV-1, HAdV-2, HAdV-3, HAdV-4, HAdV-5, HAdV-7, HAdV-21, and HAdV-55, and 4A1 specifically recognized HAdV-1, HAdV-2, HAdV-3, HAdV-5, HAdV-7, HAdV-21, and HAdV-55. IFAs showed that 1F10, 8D3, and 4A1 exhibited highly selective localization to A549 cells infected with HAdV-3 and HAdV-55. Finally, two antibody pairs that could detect hexon antigens HAdV-3 and HAdV-55 at low concentrations were developed. The monoclonal antibodies developed in this study show potential for detecting human adenoviruses.

IMPORTANCE
In this study, we selected the three most conserved antigenic fragments of human adenovirus to prepare a murine monoclonal antibody for the first time, and human adenovirus antigenic fragments with heretofore unheard of degrees of conservatism were isolated. The three monoclonal antibodies with the ability to recognize human respiratory adenovirus over a broad spectrum were screened by hybridoma and monoclonal antibody preparation. Human adenovirus infections are serious; however, therapeutic drugs and diagnostic reagents are scarce. Thus, to reduce the serious consequences of human viral infections and adenovirus pneumonitis, early diagnosis of infection is required. The present study provides three monoclonal antibodies capable of recognizing a wide range of human adenoviruses, thereby offering guidance for subsequent research and development.
Analysis on the change of gut microbiota and metabolome in lung transplant patients
Authors: Hou Zhichao , Zhang Tangjuan , Ding Zheng , Qian Ting , Wang Peng , Wu Bo , Pan Xue , Li Xiangnan 
Published: February 2024

ABSTRACT

Previous studies have shown that the gut microbiota and its metabolites are associated with the success of organ transplantation. However, the specific changes in the gut microbiota of lung transplant patients remain unclear. Hence, this study aimed to elucidate the interplay between the gut microbiota, metabolome, and lung transplantation outcomes. Using 16S metagenomics sequencing and untargeted metabolic profiling, we conducted a comprehensive analysis of gut microbial and metabolic alterations in lung transplant recipients relative to non-transplant group. Our findings revealed the predominance of
Enterococcus
and
Streptococcus
genera within the lung transplant cohort, accompanied by the significant reduction in
Bacteroides
,
Epulopiscium
,
Faecalibacterium
, and
Prevotella
abundance. In addition, a significant reduction in ATRA (all-trans retinoic acid) levels and suppression of IgA production were observed in lung transplant recipients, which were found to be closely associated with the
Enterococcus
genus. It was speculated that the association might have implications for the prognosis of lung transplant patients. Notably, the differences in gut microbial composition and metabolomic profiles between successful transplant recipients and those experiencing chronic rejection were not statistically significant. These novel insights shed light on the putative implications of the gut microbiota and metabolome in shaping lung transplantation outcomes, and provide a foundation for future investigations and targeted therapeutic interventions.

IMPORTANCE

This study has profound implications for lung transplantation as it uncovers the important role of gut microbiota and metabolome in shaping transplantation outcomes. The identification of dominant bacterial genera, such as
Enterococcus
and
Streptococcus
, within the lung transplant cohort, along with the significant decrease in
Bacteroides
,
Epulopiscium
,
Faecalibacterium
, and
Prevotella
abundance, reveals potential microbial imbalances associated with lung transplantation. In addition, a significant reduction in ATRA (all-trans retinoic acid) levels and suppression of IgA production were observed in lung transplant recipients, which were found to be closely associated with the
Enterococcus
genus. It was speculated that the association might have implications for the prognosis of lung transplant patients. These findings hold immense clinical significance as they lay the groundwork for future research and targeted therapeutic interventions. Understanding the impact of the gut microbiota and metabolome on lung transplantation outcomes offers promising avenues for improving transplantation patient prognosis.
Jura-Cretaceous synorogenic magmatism and relations to supercontinental rifting in the northwestern U.S. Cordillera
Authors: Gray Keith D. , Johnson K. , Foster David A. , Isakson V. 
Published: February 2024

AbstractChanges in lithospheric composition and strength associated with rifting of the Rodinian supercontinent (ca. 780–485 Ma) served to localize Mesozoic tectonic activity in the McCall region of west-central Idaho, USA. Although discrimination diagrams support slab failure melting, ca. 150–121 Ma calcic magmatism in the Hazard Creek complex and chemically similar intrusive rocks of northeastern Oregon, USA (e.g., Cornucopia stock), is best explained by progressive loading of oceanic crust. Westward-directed thrusting across the Laurentian continental margin and adjacent island-arc terranes (Olds Ferry/Wallowa; Blue Mountains province) led to partial melting of metabasaltic source rocks at pressures and depths sufficient for garnet stability (&gt;10 kbar, ~35 km). Early pluton emplacement during right-oblique arc–continent collision overlapped in time with subduction zone reorganization, which involved a change in dip direction (westward to eastward) under the accreting Blue Mountains block. Ensuing magmatic activity predated and was concurrent with ca. 116 Ma thrust reactivation of the Wallowa/Olds Ferry boundary, which temporally overlapped with contractional deformation along the terrane–continent accretionary boundary. Later synorogenic magmatism was focused along the accretionary boundary, where rising anatectic melts were caught between the eastward-impinging/northward-migrating (obliquely colliding) terrane block and continental margin backstop (Rodinian rift architecture). Middle Cretaceous dextral transpression viewed in this manner precludes the need for an outboard “hit-and-run” collider (Insular superterrane) and thus, a post-accretion shear zone in western Idaho.
A model-based approach to estimating the prevalence of disease combinations in South Africa
Authors: Johnson Leigh F , Kassanjee Reshma , Folb Naomi , Bennett Sarah , Boulle Andrew , Levitt Naomi S , Curran Robyn , Bobrow Kirsty , Roomaney Rifqah A , Bachmann Max O , Fairall Lara R 
Published: February 2024

BackgroundThe development of strategies to better detect and manage patients with multiple long-term conditions requires estimates of the most prevalent condition combinations. However, standard meta-analysis tools are not well suited to synthesising heterogeneous multimorbidity data.MethodsWe developed a statistical model to synthesise data on associations between diseases and nationally representative prevalence estimates and applied the model to South Africa. Published and unpublished data were reviewed, and meta-regression analysis was conducted to assess pairwise associations between 10 conditions: arthritis, asthma, chronic obstructive pulmonary disease (COPD), depression, diabetes, HIV, hypertension, ischaemic heart disease (IHD), stroke and tuberculosis. The national prevalence of each condition in individuals aged 15 and older was then independently estimated, and these estimates were integrated with the ORs from the meta-regressions in a statistical model, to estimate the national prevalence of each condition combination.ResultsThe strongest disease associations in South Africa are between COPD and asthma (OR 14.6, 95% CI 10.3 to 19.9), COPD and IHD (OR 9.2, 95% CI 8.3 to 10.2) and IHD and stroke (OR 7.2, 95% CI 5.9 to 8.4). The most prevalent condition combinations in individuals aged 15+ are hypertension and arthritis (7.6%, 95% CI 5.8% to 9.5%), hypertension and diabetes (7.5%, 95% CI 6.4% to 8.6%) and hypertension and HIV (4.8%, 95% CI 3.3% to 6.6%). The average numbers of comorbidities are greatest in the case of COPD (2.3, 95% CI 2.1 to 2.6), stroke (2.1, 95% CI 1.8 to 2.4) and IHD (1.9, 95% CI 1.6 to 2.2).ConclusionSouth Africa has high levels of HIV, hypertension, diabetes and arthritis, by international standards, and these are reflected in the most prevalent condition combinations. However, less prevalent conditions such as COPD, stroke and IHD contribute disproportionately to the multimorbidity burden, with high rates of comorbidity. This modelling approach can be used in other settings to characterise the most important disease combinations and levels of comorbidity.
Health journal coverage of climate change and health: a bibliometric study
Authors: Muhia Joy , Rethlefsen Melissa L , Rossington Ben , Wedmore Florence , Pattnaik Anandita , Smith Richard , Schroter Sara 
Published: February 2024

ObjectivesTo find what proportion of a broad set of health journals have published on climate change and health, how many articles they have published, and when they first published on the subject.DesignBibliometric study.Setting and participantsWe conducted electronic searches in Ovid MEDLINE ALL for articles about climate change and human health published from 1860 to 31 December 2022 in 330 health journals. There were no limits by language or publication type. Results were independently screened by two raters for article eligibility.ResultsAfter screening there were 2932 eligible articles published across 253 of the 330 journals between 1947 and 2022; most (2795/2932; 95%) were published in English. A few journals published articles in the early 90s, but there has been a rapid increase since about 2006. We were unable to categorise the types of publication but estimate that fewer than half are research papers. While articles were published in journals in 39 countries, two-thirds (1929/2932; 66%) were published in a journal published in the UK or the USA. Almost a quarter (77/330; 23%) of the journals published no eligible articles, and almost three-quarters (241/330; 73%) published five articles or fewer. The publication of joint editorials in over 200 journals in 2021 and 2022 boosted the number of journals publishing something on climate change and health. A third of the (112/330; 34%) journals in our sample published at least one of the joint editorials, and almost a third of those (32/112; 29%) were publishing on climate change and health for the first time.ConclusionsHealth journals are rapidly increasing the amount they publish on climate change and health, but despite climate change being the major threat to global health many journals had until recently published little or nothing. A joint editorial published in multiple journals increased coverage, and for many journals it was the first thing they published on climate change and health.
Effectiveness and cost effectiveness of pharmacological thromboprophylaxis for medical inpatients: decision analysis modelling study
Authors: Davis Sarah , Goodacre Steve , Horner Daniel , Pandor Abdullah , Holland Mark , de Wit Kerstin , Hunt Beverley J , Griffin Xavier Luke 
Published: February 2024

ObjectiveTo determine the balance of costs, risks, and benefits for different thromboprophylaxis strategies for medical patients during hospital admission.DesignDecision analysis modelling study.SettingNHS hospitals in England.PopulationEligible adult medical inpatients, excluding patients in critical care and pregnant women.InterventionsPharmacological thromboprophylaxis (low molecular weight heparin) for all medical inpatients, thromboprophylaxis for none, and thromboprophylaxis given to higher risk inpatients according to risk assessment models (Padua, Caprini, IMPROVE, Intermountain, Kucher, Geneva, and Rothberg) previously validated in medical cohorts.Main outcome measuresLifetime costs and quality adjusted life years (QALYs). Costs were assessed from the perspective of the NHS and Personal Social Services in England. Other outcomes assessed were incidence and treatment of venous thromboembolism, major bleeds including intracranial haemorrhage, chronic thromboembolic complications, and overall survival.ResultsOffering thromboprophylaxis to all medical inpatients had a high probability (>99%) of being the most cost effective strategy (at a threshold of £20 000 (€23 440; $25 270) per QALY) in the probabilistic sensitivity analysis, when applying performance data from the Padua risk assessment model, which was typical of that observed across several risk assessment models in a medical inpatient cohort. Thromboprophylaxis for all medical inpatients was estimated to result in 0.0552 additional QALYs (95% credible interval 0.0209 to 0.1111) while generating cost savings of £28.44 (−£47 to £105) compared with thromboprophylaxis for none. No other risk assessment model was more cost effective than thromboprophylaxis for all medical inpatients when assessed in deterministic analysis. Risk based thromboprophylaxis was found to have a high (76.6%) probability of being the most cost effective strategy only when assuming a risk assessment model with very high sensitivity is available (sensitivity 99.9% and specificity 23.7%vbase case sensitivity 49.3% and specificity 73.0%).ConclusionsOffering pharmacological thromboprophylaxis to all eligible medical inpatients appears to be the most cost effective strategy. To be cost effective, any risk assessment model would need to have a very high sensitivity resulting in widespread thromboprophylaxis in all patients except those at the very lowest risk, who could potentially avoid prophylactic anticoagulation during their hospital stay.
Understanding effect size: an international online survey among psychiatrists, psychologists, physicians from other medical specialities, dentists and other health professionals
Authors: Heimke Ferdinand , Furukawa Yuki , Siafis Spyridon , Johnston Bradley C. , Engel Rolf R. , Furukawa Toshi A , Leucht Stefan 
Published: February 2024

Background and objectiveVarious ways exist to display the effectiveness of medical treatment options. This study examined various psychiatric, medical and allied professionals’ understanding and perceived usefulness of eight effect size indices for presenting both dichotomous and continuous outcome data.MethodsWe surveyed 1316 participants from 13 countries using an online questionnaire. We presented hypothetical treatment effects of interventions versus placebo concerning chronic pain using eight different effect size measures. For each index, the participants had to judge the magnitude of the shown effect, to indicate how certain they felt about their own answer and how useful they found the given effect size index.FindingsOverall, 762 (57.9%) participants fully completed the questionnaire. In terms of understanding, the best results emerged when both the control event rate (CER) and the experimental event rate (EER) were presented. The difference in minimal importance difference units (MID unit) was understood worst. Respondents also found CER and EER to be the most useful presentation approach while they rated MID unit as the least useful. Confidence in the risk ratio ranked high, even though it was rather poorly understood.Conclusions and clinical implicationsFor dichotomous outcomes, presenting the effects in terms of the CER and EER could lead to the most correct interpretation. Relative measures including the risk ratio must be supplemented with absolute measures such as the CER and EER. Effects on continuous outcomes were better understood through standardised mean differences than mean differences. These can also be supplemented by dichotomised CER and EER.
Assessment of performance and safety of Corneal Chamber hypothermic storage medium and PSS-L corneal rinsing solution in human and porcine corneas
Authors: Giurgola Laura , Rodella Umberto , Gatto Claudio , Rossi Orietta , Honisch Claudia , Ragazzi Eugenio , Ruzza Paolo , Ferrari Stefano , D'Amato Tóthová Jana 
Published: February 2024

PurposeTo prove the safety and performance of the hypothermic corneal storage medium "Corneal Chamber" and the rinsing solution "PSS-L" in support of the newConformité Européenne(CE) certification process in accordance with the Medical Device Regulation.MethodsFifteen (n=15) human donor corneas and 11 (n=11) porcine corneas were evaluated for the following parameters: endothelial cell density (ECD) and mortality, percentage of hexagonal cells (HEX%), coefficient of cellular area variation (CV%) and corneal transparency at Day 0 and after 14±1 days of storage in Corneal Chamber medium at 2–8°C. Then, the same parameters were assessed after rinsing of corneas in PSS-L for 1 min at room temperature. Evaluation of gentamicin sulfate carryover after corneal storage and PSS-L rinsing was performed by ultra-high performance liquid chromatography analysis on human corneas homogenates.ResultsHuman and porcine corneas stored in Corneal Chamber medium showed a good overall quality of the tissue according to the quality parameters evaluated. In particular, mean ECD, HEX% and CV% did not show statistically significant changes at the end of storage and endothelial mortality increased to 3.1±3.3 and 7.8±3.5% in human and porcine corneas, respectively. Tissue rinsing with PSS-L did not affect the quality parameters evaluated before and gentamicin sulfate residues were absent in human corneas.ConclusionsCorneal preservation in Corneal Chamber medium at 2–8°C for 14 days and the corneal rinse with PSS-L are safe and effective procedures allowing the preservation of the corneal quality parameters as well as the complete elimination of gentamicin sulfate from the tissues before transplantation.Cite Now
Percutaneous intramyocardial septal radiofrequency ablation after 5-year follow-up
Authors: Ta Shengjun , Li Jing , Hsi David H , Hu Rui , Lei Changhui , Shan Bo , Li Wenxia , Wang Jing , Wang Bo , Kang Nan , Li Xiaojuan , Liu Jiani , Qi Caixia , Huang Junzhe , Han Yupeng , Ruan Fangqi , Zhang Jun , Liu Liwen 
Published: February 2024

ObjectiveThe objective is to evaluate the 5-year follow-up results of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) for hypertrophic obstructive cardiomyopathy (HOCM), including clinical status, electrocardiographic and echocardiographic characteristics.Methods27 patients (age: 44.3±15.5 years; 67% men, 33% women) with severely symptomatic HOCM who underwent PIMSRA from October 2016 to September 2017 were included. Their clinical status, resting and exercise stress echocardiography, electrocardiography and cardiac MRI (CMRI) after long-term follow-up were assessed.ResultsOne patient died of intracerebral haemorrhage 1 year post procedurally. The New York Heart Association class, Canadian Cardiovascular Society class and exercise-induced syncopal attacks improved significantly in 26 patients (all p<0.01). Left ventricular (LV) outflow tract gradients revealed sustained reduction (resting: from 95.0 to 9.0 mm Hg, p<0.001; post exercise: from 130.5 to 21.0 mm Hg, p<0.001). The echocardiographic evaluation revealed decreased septal thickness, LV posterior wall thickness and left atrial (LA) diameter (all p<0.001). CMRI data revealed decrease in LV mass index and LA volume index and increase in LV end-diastolic volume index and stroke volume index between baseline and long-term follow-up (all p<0.05). The global longitudinal strain of LV improved from (−11.9%±3.7%) before the procedure to (−13.1%±3.9%) at the last check (p<0.001). Malignant ventricular arrhythmia and heart failure events were not observed.ConclusionsPIMSRA can effectively alleviate symptoms in patients with HOCM and improve their hemodynamics in the long term.Trial registration numberNCT02888132.
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
Authors: Ren Shengxiang , Wang Xicheng , Han Bao-Hui , Pan Yueyin , Zhao Jun , Cheng Yufeng , Hu Sheng , Liu Tianshu , Li Yalun , Cheng Ying , Feng Jifeng , Yi Shanyong , Gu Shanzhi , Gao Shegan , Luo Yongzhong , Liu Ying , Liu Caigang , Duan Huijie , Wang Shuni , Yang Xinfeng , Fan Jia , Zhou Caicun 
Published: February 2024

BackgroundThe combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase inhibitor) as a first-line treatment for advanced or metastatic NSCLC patients with a programmed death ligand-1 (PD-L1) tumor proportion score (TPS) of ≥1%, in an open-label, multicenter, phase 2 basket trial.MethodsEligible patients received camrelizumab (200 mg once every 3 weeks via intravenous infusion) plus oral famitinib at an initial dose of 20 mg once daily. The primary endpoint was the objective response rate (ORR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors V.1.1. Key secondary endpoints included disease control rate (DCR), duration of respons, progression-free survival (PFS), overall survival (OS), 12-month OS rate, and safety profile.ResultsOf the enrolled 41 patients, 21 (51.2%) had a PD-L1 TPS of 1–49%. As of the cut-off date on June 22, 2022, the combination regimen of camrelizumab and famitinib achieved an ORR of 53.7% (95% CI 37.4% to 69.3%) and a DCR of 92.7% (95% CI 80.1% to 98.5%). The median PFS was 16.6 months (95% CI 8.3 to not reached), and OS data were not yet mature, with an estimated 12-month OS rate of 76.8% (95% CI 60.0% to 87.3%). The most common treatment-related adverse events of grade 3 or higher included hypertension (22.0%), increased alanine aminotransferase (12.2%), decreased neutrophil count (9.8%), proteinuria (7.3%), decrease platelet count (7.3%), and hypokalemia (7.3%). One (2.4%) patient died from grade 5 hemoptysis, which was considered possibly related to the study treatment by the investigator.ConclusionCamrelizumab plus famitinib demonstrated promising antitumor activity in advanced or metastatic NSCLC patients and had an acceptable safety profile. These findings suggest that this combination regimen could be an alternative therapeutic option and warrant further investigation.Trial registration numberNCT04346381.